Cancer of the organs of the reproductive system in women with type 2 diabetes. effects of antidiabetic therapy

Abstract

OBJECTIVE: The aim: to investigate the prevalence of cancer of the reproductive system in women with type 2 diabetes, and to examine the impact of antidiabetic therapy on cancer risk of this localization. PATIENTS AND METHODS: Materials and methods: The study included a retrospective analysis of medical records of women with T2D with first diagnosed cancer during 2012-2016. The bases for the study were specialized medical institutions in Ivano-Frankivsk region. The obtained results were processed using statistical programs "Microsoft Excel" and "Statistika-12". RESULTS: Results: Breast, uterine, and ovarian cancer were detected in 202 postmenopausal women, 63.92% from the total number of cancer cases in women. An increased risk of breast [OR = 1.24; 95% CI (1.04 - 1.50) P = 0.019] and uterine cancer [OR = 1.32; 95% CI (1.02 - 1.69) P = 0.040] has been identified. Most often, before the detection of cancer, women received combination therapy with sulfonylurea and metformin (83 patients (57.64%)) with BMI 32.64 ± 3.69 kg/m2. The difference between risk of cancer on metformin monotherapy and on sulfonylurea monotherapy [OR = 2.17; 95% CI (0.88 - 5.36) P = 0.141] or on combination therapy [OR = 1.68; 95% CI (0.76 - 3.74) P = 0.276] was not found. CONCLUSION: Conclusions: Postmenopausal women have an increased risk of breast and uterine cancer and are recommended to be screened for these diseases. The highest incidence of cancer in women with obesity on combination therapy requires the use of antidiabetic drugs that are able to correct BMI as a second-line therapy.